The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 17th 2025
Intellectual disabilities, food allergies, and asthma were all more common in children who took multiple courses of antibiotics before the age of 2 years.
Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD
July 9th 2024Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.
Watch
Five Children, 2 Hearing-Improved Ears Each: Successful DFNB9 Gene Therapy
July 8th 2024The interim results of a single-arm trial in children with autosomal recessive deafness 9 (DFNB9) show the benefits of binaural administration of gene therapy: better hearing with no serious adverse effects.
Read More
NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib
July 4th 2024William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importance of monitoring treatment response.
Watch
Tailoring CDK4/6 Inhibitor Treatment to Patient Needs
July 4th 2024A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.
Watch
VEXAS Syndrome Often Misdiagnosed as Pyoderma Gangrenosum
July 3rd 2024In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology and with systemic symptoms.
Read More
Study Finds Ravulizumab Effective in Treating Acetylcholine Receptor–Positive Generalized MG
July 2nd 2024More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful reduction in MG activities of daily living scores.
Read More
Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
July 2nd 2024The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.
Watch